[Asia Economy Reporter Eunmo Koo] Rokit Healthcare has selected KB Securities as the lead underwriter and is making full-scale moves to list on the KOSDAQ market.
Rokit Healthcare, a specialized company in diabetic foot ulcer treatment human organ regeneration platform (hereinafter referred to as the diabetic foot regeneration treatment platform) utilizing the bio 4D printer ‘Doctor In Vivo,’ announced on the 14th that it has signed an underwriting contract with KB Securities aiming for a KOSDAQ market listing next year.
Rokit Healthcare is preparing for an initial public offering (IPO) with KB Securities as the lead underwriter and Mirae Asset Daewoo as the joint underwriter. KB Securities, which signed the underwriting contract this time, ranked first in the ECM sector in the first quarter of this year and has extensive experience and expertise in listing numerous bio companies such as PharmAbcine, Bridge Biotherapeutics, and Syntekabio.
Last year, Rokit Healthcare developed the diabetic foot regeneration treatment platform using the bio 4D printer ‘Doctor In Vivo.’ A company official explained, “The platform is strengthening its position in the diabetic foot treatment field, having signed technology export cooperation contracts selling to 48 countries. We have independently developed 3D biotissue processing, bioink, cell sheets, and human tissue fusion manufacturing technology (Biofabrication), aiming to provide a safe autologous organ regeneration platform service applicable to all fields suitable for customized regenerative medicine.”
Yoo Seok-hwan, CEO of Rokit Healthcare, said, “Combining my experience as former CEO of Celltrion Healthcare and bio 4D printing technology, we will export the cutting-edge organ regeneration medical platform to the global market. We will also strive to grow into a global company by expanding into the anti-aging market, including patient-customized organ regeneration to reduce medical expenses.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
